Approval · Notice of Compliance 2027 · 1999
ACTONEL: Notice of Compliance 2027
Issued August 18, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2027
- Date
- August 18, 1999
- Company
- Procter & Gamble Pharmaceuticals Canada, IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACTONEL | 02239146 | Cancelled Post Market |
Medicinal ingredients
- RISEDRONATE SODIUM 30 MG per TAB